NASDAQ: AMTI | Healthcare / Biotechnology / USA |
1.96 | 0 | 0.00 | Vol 108.40K | 1Y Perf -93.73% |
Aug 12th, 2022 16:00 DELAYED |
BID | 1.92 | ASK | 1.99 | ||
Open | 1.95 | Previous Close | 1.96 | ||
Pre-Market | - | After-Market | 1.94 | ||
- - | -0.02 -1.02% |
Target Price | 17.80 | Analyst Rating | Moderate Buy 1.67 | |
Potential % | 808.16 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | 100/100/-11 | Value Ranking | — - | |
Insiders Value % 3/6/12 mo. | 100/100/-35 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/57 | Income Ranking | — - | |
Price Range Ratio 52W % | 0.79 | Earnings Rating | — | |
Market Cap | 76.24M | Earnings Date | 9th Aug 2022 | |
Alpha | -0.08 | Standard Deviation | 0.22 | |
Beta | 1.76 |
Today's Price Range 1.880.00 | 52W Range 1.7133.28 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -1.51% | ||
1 Month | -24.03% | ||
3 Months | -51.96% | ||
6 Months | -74.28% | ||
1 Year | -93.73% | ||
3 Years | - | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -88.09 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -72.52 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -76.44 | |||
Return on invested Capital Q | -23.82 | |||
Return on invested Capital Y | -60.13 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.60 | ||||
0.78 | ||||
- | ||||
- | ||||
-0.70 | ||||
-2.57 | ||||
0.78 | ||||
2.51 | ||||
17.75M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.90 | ||||
6.30 | ||||
0.25 | ||||
0.38 | ||||
- | ||||
Leverage Ratio | 1.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.65 | -0.93 | -43.08 |
Q01 2022 | -0.70 | -1.10 | -57.14 |
Q04 2021 | -0.63 | -0.78 | -23.81 |
Q03 2021 | -0.60 | -0.68 | -13.33 |
Q02 2021 | -0.58 | -0.62 | -6.90 |
Q01 2021 | -0.57 | -0.58 | -1.75 |
Q04 2020 | -0.46 | -0.38 | 17.39 |
Q03 2020 | -0.41 | -0.48 | -17.07 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | - |
Estimated EPS Next Report | -0.65 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 108.40K |
Shares Outstanding | 38.90K |
Shares Float | 13.01M |
Trades Count | 1.54K |
Dollar Volume | 212.48K |
Avg. Volume | 324.66K |
Avg. Weekly Volume | 241.43K |
Avg. Monthly Volume | 318.77K |
Avg. Quarterly Volume | 413.78K |
Applied Molecular Transport Inc. (NASDAQ: AMTI) stock closed at 1.96 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 108.40K shares and market capitalization of 76.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 49 people. Applied Molecular Transport Inc. CEO is Tahir Mahmood.
The one-year performance of Applied Molecular Transport Inc. stock is -93.73%, while year-to-date (YTD) performance is -85.98%. AMTI stock has a five-year performance of %. Its 52-week range is between 1.71 and 33.28, which gives AMTI stock a 52-week price range ratio of 0.79%
Applied Molecular Transport Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.78, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -72.52%, a ROC of -76.44% and a ROE of -88.09%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Applied Molecular Transport Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Applied Molecular Transport Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Applied Molecular Transport Inc. is Moderate Buy (1.67), with a target price of $17.8, which is +808.16% compared to the current price. The earnings rating for Applied Molecular Transport Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Applied Molecular Transport Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Applied Molecular Transport Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.28, ATR14 : 0.25, CCI20 : -30.15, Chaikin Money Flow : -0.34, MACD : -0.23, Money Flow Index : 29.80, ROC : 1.03, RSI : 32.09, STOCH (14,3) : 58.14, STOCH RSI : 1.00, UO : 46.22, Williams %R : -41.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Applied Molecular Transport Inc. in the last 12-months were: Bittoo Kanwar (Option Excercise at a value of $74 970), David A. Lamond (Buy at a value of $210 850), Helen S. Kim (Sold 9 986 shares of value $300 331 ), Randall Mrsny (Buy at a value of $52 464), Shawn Cross (Option Excercise at a value of $46 100), Shawn Cross (Sold 10 000 shares of value $301 193 ), Tahir Mahmood (Buy at a value of $23 640)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Strong Buy |
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
CEO: Tahir Mahmood
Telephone: +1 650 392-0420
Address: 1 Tower Place, South San Francisco 94080, CA, US
Number of employees: 49
Mon, 25 Apr 2022 15:35 GMT Applied Molecular Transport (AMTI) Receives a Buy from JMP Securities
- TipRanks. All rights reserved.Tue, 01 Mar 2022 10:38 GMT Applied Molecular Transport (AMTI) Gets a Buy Rating from Leerink Partners
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.